These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1040 related articles for article (PubMed ID: 19629984)
1. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy. Takenaka D; Ohno Y; Matsumoto K; Aoyama N; Onishi Y; Koyama H; Nogami M; Yoshikawa T; Matsumoto S; Sugimura K J Magn Reson Imaging; 2009 Aug; 30(2):298-308. PubMed ID: 19629984 [TBL] [Abstract][Full Text] [Related]
2. Non-small cell lung cancer: whole-body MR examination for M-stage assessment--utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Ohno Y; Koyama H; Onishi Y; Takenaka D; Nogami M; Yoshikawa T; Matsumoto S; Kotani Y; Sugimura K Radiology; 2008 Aug; 248(2):643-54. PubMed ID: 18539889 [TBL] [Abstract][Full Text] [Related]
3. Diffusion-weighted MR imaging using FASE sequence for 3T MR system: Preliminary comparison of capability for N-stage assessment by means of diffusion-weighted MR imaging using EPI sequence, STIR FASE imaging and FDG PET/CT for non-small cell lung cancer patients. Ohno Y; Koyama H; Yoshikawa T; Takenaka D; Kassai Y; Yui M; Matsumoto S; Sugimura K Eur J Radiol; 2015 Nov; 84(11):2321-31. PubMed ID: 26231045 [TBL] [Abstract][Full Text] [Related]
4. Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma. Mosavi F; Johansson S; Sandberg DT; Turesson I; Sörensen J; Ahlström H AJR Am J Roentgenol; 2012 Nov; 199(5):1114-20. PubMed ID: 23096187 [TBL] [Abstract][Full Text] [Related]
5. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy. Ohno Y; Koyama H; Yoshikawa T; Matsumoto K; Aoyama N; Onishi Y; Sugimura K AJR Am J Roentgenol; 2012 Jan; 198(1):75-82. PubMed ID: 22194481 [TBL] [Abstract][Full Text] [Related]
6. Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up? Chen W; Jian W; Li HT; Li C; Zhang YK; Xie B; Zhou DQ; Dai YM; Lin Y; Lu M; Huang XQ; Xu CX; Chen L Magn Reson Imaging; 2010 Jun; 28(5):613-20. PubMed ID: 20418042 [TBL] [Abstract][Full Text] [Related]
7. Non-small cell carcinoma: comparison of postoperative intra- and extrathoracic recurrence assessment capability of qualitatively and/or quantitatively assessed FDG-PET/CT and standard radiological examinations. Onishi Y; Ohno Y; Koyama H; Nogami M; Takenaka D; Matsumoto K; Yoshikawa T; Matsumoto S; Maniwa Y; Nishimura Y; Sugimura K Eur J Radiol; 2011 Sep; 79(3):473-9. PubMed ID: 20547021 [TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis. Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513 [TBL] [Abstract][Full Text] [Related]
9. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system. Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008 [TBL] [Abstract][Full Text] [Related]
10. Supplemental value of diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) technique to whole-body magnetic resonance imaging in detection of bone metastases from thyroid cancer. Sakurai Y; Kawai H; Iwano S; Ito S; Ogawa H; Naganawa S J Med Imaging Radiat Oncol; 2013 Jun; 57(3):297-305. PubMed ID: 23721138 [TBL] [Abstract][Full Text] [Related]
11. Comparison of the utility of whole-body MRI with and without contrast-enhanced Quick 3D and double RF fat suppression techniques, conventional whole-body MRI, PET/CT and conventional examination for assessment of recurrence in NSCLC patients. Ohno Y; Nishio M; Koyama H; Yoshikawa T; Matsumoto S; Takenaka D; Seki S; Tsubakimoto M; Sugimura K Eur J Radiol; 2013 Nov; 82(11):2018-27. PubMed ID: 24012452 [TBL] [Abstract][Full Text] [Related]
12. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging. Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400 [TBL] [Abstract][Full Text] [Related]
14. Whole-body MR imaging vs. FDG-PET: comparison of accuracy of M-stage diagnosis for lung cancer patients. Ohno Y; Koyama H; Nogami M; Takenaka D; Yoshikawa T; Yoshimura M; Kotani Y; Nishimura Y; Higashino T; Sugimura K J Magn Reson Imaging; 2007 Sep; 26(3):498-509. PubMed ID: 17729341 [TBL] [Abstract][Full Text] [Related]
15. Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT. van Ufford HM; Kwee TC; Beek FJ; van Leeuwen MS; Takahara T; Fijnheer R; Nievelstein RA; de Klerk JM AJR Am J Roentgenol; 2011 Mar; 196(3):662-9. PubMed ID: 21343511 [TBL] [Abstract][Full Text] [Related]
16. Diagnostic performance of different imaging modalities in the assessment of distant metastasis and local recurrence of tumor in patients with non-small cell lung cancer. Ohno Y; Yoshikawa T; Kishida Y; Seki S; Koyama H; Yui M; Kassai Y; Aoyagi K; Kaminaga S; Sugimura K J Magn Reson Imaging; 2017 Dec; 46(6):1707-1717. PubMed ID: 28419645 [TBL] [Abstract][Full Text] [Related]
17. N stage disease in patients with non-small cell lung cancer: efficacy of quantitative and qualitative assessment with STIR turbo spin-echo imaging, diffusion-weighted MR imaging, and fluorodeoxyglucose PET/CT. Ohno Y; Koyama H; Yoshikawa T; Nishio M; Aoyama N; Onishi Y; Takenaka D; Matsumoto S; Maniwa Y; Nishio W; Nishimura Y; Itoh T; Sugimura K Radiology; 2011 Nov; 261(2):605-15. PubMed ID: 21926377 [TBL] [Abstract][Full Text] [Related]